Management of renal osteodystrophy in peritoneal dialysis patients

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The term "renal osteodystrophy" encompasses all forms of metabolic bone disease found in dialysis patients. The primary approach to the treatment of renal osteodystrophy in peritoneal dialysis (PD) patients is similar to that in hemodialysis patients. However, the increased prevalence of adynamic bone histology, together with the difficulty in judging calcium balance, the inability to practicably give intravenous vitamin D, and the clearance of vitamin D and parathyroid hormone via dialysate require a different therapeutic approach in PD compared to hemodialysis patients. Clearly, more comparative studies of new agents are needed to find the optimal approach to achieving the K/DOQI guidelines in PD patients. The unique aspects of the approach to renal osteodystrophy in PD patients are the focus of this review.

Original languageEnglish
Pages (from-to)209-216
Number of pages8
JournalPeritoneal Dialysis International
Volume24
Issue number3
StatePublished - May 2004

Fingerprint

Chronic Kidney Disease-Mineral and Bone Disorder
Peritoneal Dialysis
Vitamin D
Renal Dialysis
Metabolic Bone Diseases
Dialysis Solutions
Parathyroid Hormone
Dialysis
Histology
Guidelines
Calcium
Bone and Bones
Therapeutics

Keywords

  • Calcium
  • Osteoporosis
  • Phosphorus
  • Renal osteodystrophy
  • Vitamin D

ASJC Scopus subject areas

  • Nephrology

Cite this

Management of renal osteodystrophy in peritoneal dialysis patients. / Moe, Sharon.

In: Peritoneal Dialysis International, Vol. 24, No. 3, 05.2004, p. 209-216.

Research output: Contribution to journalArticle

@article{09939b70ef134358842bb38503ef4fb6,
title = "Management of renal osteodystrophy in peritoneal dialysis patients",
abstract = "The term {"}renal osteodystrophy{"} encompasses all forms of metabolic bone disease found in dialysis patients. The primary approach to the treatment of renal osteodystrophy in peritoneal dialysis (PD) patients is similar to that in hemodialysis patients. However, the increased prevalence of adynamic bone histology, together with the difficulty in judging calcium balance, the inability to practicably give intravenous vitamin D, and the clearance of vitamin D and parathyroid hormone via dialysate require a different therapeutic approach in PD compared to hemodialysis patients. Clearly, more comparative studies of new agents are needed to find the optimal approach to achieving the K/DOQI guidelines in PD patients. The unique aspects of the approach to renal osteodystrophy in PD patients are the focus of this review.",
keywords = "Calcium, Osteoporosis, Phosphorus, Renal osteodystrophy, Vitamin D",
author = "Sharon Moe",
year = "2004",
month = "5",
language = "English",
volume = "24",
pages = "209--216",
journal = "Peritoneal Dialysis International",
issn = "0896-8608",
publisher = "Multimed Inc.",
number = "3",

}

TY - JOUR

T1 - Management of renal osteodystrophy in peritoneal dialysis patients

AU - Moe, Sharon

PY - 2004/5

Y1 - 2004/5

N2 - The term "renal osteodystrophy" encompasses all forms of metabolic bone disease found in dialysis patients. The primary approach to the treatment of renal osteodystrophy in peritoneal dialysis (PD) patients is similar to that in hemodialysis patients. However, the increased prevalence of adynamic bone histology, together with the difficulty in judging calcium balance, the inability to practicably give intravenous vitamin D, and the clearance of vitamin D and parathyroid hormone via dialysate require a different therapeutic approach in PD compared to hemodialysis patients. Clearly, more comparative studies of new agents are needed to find the optimal approach to achieving the K/DOQI guidelines in PD patients. The unique aspects of the approach to renal osteodystrophy in PD patients are the focus of this review.

AB - The term "renal osteodystrophy" encompasses all forms of metabolic bone disease found in dialysis patients. The primary approach to the treatment of renal osteodystrophy in peritoneal dialysis (PD) patients is similar to that in hemodialysis patients. However, the increased prevalence of adynamic bone histology, together with the difficulty in judging calcium balance, the inability to practicably give intravenous vitamin D, and the clearance of vitamin D and parathyroid hormone via dialysate require a different therapeutic approach in PD compared to hemodialysis patients. Clearly, more comparative studies of new agents are needed to find the optimal approach to achieving the K/DOQI guidelines in PD patients. The unique aspects of the approach to renal osteodystrophy in PD patients are the focus of this review.

KW - Calcium

KW - Osteoporosis

KW - Phosphorus

KW - Renal osteodystrophy

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=2942668040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942668040&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 209

EP - 216

JO - Peritoneal Dialysis International

JF - Peritoneal Dialysis International

SN - 0896-8608

IS - 3

ER -